From GlobeNewswire: 2025-05-22 16:50:00

Onconetix, Inc. received a delisting letter from Nasdaq due to failure to file required reports, risking removal from the Nasdaq Capital Market. The company is currently before a Panel for non-compliance with the Minimum Bid Price Rule, with a scheduled hearing date of May 27, 2025. Onconetix intends to file the necessary reports promptly to regain compliance. The company focuses on men’s health and oncology, owning Proclarix® and ENTADFI for prostate cancer and benign prostatic hyperplasia treatment. For more information, visit www.onconetix.com. Contact Onconetix at 201 E. Fifth Street, Suite 1900, Cincinnati, OH 45202 or call (513) 620-4101. Investor relations can be reached at [email protected].



Read more at GlobeNewswire: Onconetix, Inc. Announces Receipt of Additional Notice from